Core Insights - CervoMed Inc. (NASDAQ:CRVO) is recognized as one of the top 10 stocks under $5 with potential for significant growth [1] Financial Performance - For the year 2025, CervoMed reported a net loss of $27.0 million and R&D expenses of $21.8 million, with cash reserves of $20.9 million as of December 31, 2025, indicating a runway of approximately six months [4] Clinical Developments - The company announced advancements in its neflamapimod program for dementia with Lewy bodies (DLB) and reported favorable Phase 2b RewinD-LB data at CTAD 2025 [2][3] - An agreement with the FDA and international authorities has been reached regarding the design of a Phase 3 trial, expected to start in late 2026 [3] Analyst Insights - Roth Capital analyst Boobalan Pachaiyappan reduced the price target for CervoMed from $19 to $11 while maintaining a "Buy" rating, noting that results were in line with expectations but indicating potential capital raising needs under less favorable terms [5] Company Overview - CervoMed is a clinical-stage biotechnology firm focused on CNS-targeted therapeutics, particularly neflamapimod, aimed at treating neurodegenerative conditions such as dementia with Lewy bodies and stroke rehabilitation [6]

CervoMed FY Conference Summary Company Overview - **Company**: CervoMed (NasdaqCM:CRVO) - **Focus**: Development of oral drugs for neurodegenerative diseases, including dementia with Lewy bodies (DLB), ALS, and frontotemporal dementia (FTD) [1][2] Industry Insights - **Dementia with Lewy Bodies (DLB)**: - DLB is the second most common progressive dementia after Alzheimer's disease, affecting over 700,000 individuals in the U.S. [8] - Current treatments are limited to symptomatic therapies, with no approved therapies in the U.S. or EU [9] - DLB progresses faster than Alzheimer's, with a typical timeline from diagnosis to nursing home care being around two years [10] - Diagnosis of DLB is challenging, with only about 50% of patients receiving a clinical diagnosis [13] Core Product: Neflamapimod - **Mechanism of Action**: Neflamapimod is a p38 alpha inhibitor, designed to treat synaptic dysfunction associated with DLB [15][18] - **Clinical Data**: - Positive results from Phase IIa study showed improvements in cognitive function and biomarkers of neurodegeneration [24] - Phase IIb study faced challenges due to manufacturing issues but later batches showed significant clinical efficacy [27] - The upcoming Phase III study will involve 300 patients over 32 weeks, focusing on CDR Sum of Boxes as the primary endpoint [28] Clinical Development and Regulatory Engagement - **FDA Engagement**: CervoMed received alignment from the FDA on the design of the Phase III study and potential registration path [28] - **Patient Enrollment Strategy**: Focus on DLB patients without Alzheimer's co-pathology to enhance clinical efficacy [30] - **Dose Confirmation**: The confirmed dose for Phase III will be 50 mg TID, increased from 40 mg in Phase IIb to ensure adequate plasma concentrations [32] Market Potential - **Patient Population**: Estimated 360,000 DLB patients without Alzheimer's co-pathology in the U.S., with significant markets in Europe and Asia [42] - **Commercial Opportunity**: The focus on precision medicine and biomarker-driven patient selection is expected to enhance the drug's marketability and align with payer expectations for value-based pricing [43] Key Milestones and Future Programs - **Upcoming Clinical Data**: Additional programs in recovery after stroke and primary progressive aphasia are expected to yield clinical or biomarker data by mid-year [61][62] - **Recognition**: CervoMed has been selected for the ExPALS program, which supports promising new therapies in ALS, further validating its scientific approach [62] Conclusion - CervoMed is positioned to address significant unmet needs in the neurodegenerative disease space, particularly with its lead asset, neflamapimod, which shows promise in treating DLB and potentially other conditions. The company is on track for a pivotal Phase III study and has a robust pipeline of additional programs.

Core Insights - New analyses from the Phase 2b RewinD-LB clinical trial indicate that DLB patients with lower plasma pTau181 levels experienced greater clinical benefits from neflamapimod, suggesting its potential to target the underlying causes of dementia with Lewy bodies (DLB) [1][2][12] - The findings support the company's patient enrichment strategy and dosing regimen for the upcoming Phase 3 trial [1][2] Clinical Trial Details - The RewinD-LB trial included an initial randomized phase comparing neflamapimod to placebo, followed by a neflamapimod-only extension phase [3][8] - In the initial phase, participants did not achieve expected plasma drug concentration levels, resulting in no statistically significant improvement on the primary endpoint [3][4] - The extension phase with a new batch of capsules (DP Batch B) showed statistically significant and clinically meaningful slowing of disease progression [4] Treatment Response and Biomarkers - Treatment response increased across DLB patient subgroups with lower pTau181 levels, indicating a higher likelihood of patients without Alzheimer's disease (AD) co-pathology benefiting from neflamapimod [2][5] - The analyses revealed a consistent improvement in clinical endpoints at progressively lower plasma pTau181 levels, with a significant difference in CDR-SB scores between treatment groups [5][6] Future Directions - The company plans to initiate a global Phase 3 trial in the second half of 2026, focusing on patients with DLB and low pTau181 levels [14] - The planned trial will utilize a pTau181 cut-off of <21 pg/mL, estimated to include 80-90% of patients without AD co-pathology, who are believed to be most likely to respond to treatment [6][12] Drug Mechanism and Efficacy - Neflamapimod is an investigational drug that inhibits p38 MAP kinase, targeting neuroinflammation and synaptic dysfunction [12][13] - Previous studies have shown that neflamapimod can restore synaptic function and improve cognitive and functional outcomes in DLB patients [13]

Core Insights - New analyses indicate that dementia with Lewy bodies (DLB) patients with lower plasma pTau181 levels experienced greater clinical benefits from neflamapimod in a Phase 2b clinical trial, suggesting a potential to target the underlying disease biology [1][2][5] - The findings support the company's patient enrichment strategy and dosing regimen for the upcoming Phase 3 trial [1][2] Clinical Trial Details - The RewinD-LB Phase 2b trial included an initial randomized phase comparing neflamapimod to placebo, followed by a neflamapimod-only extension phase [3][10] - In the initial phase, participants did not achieve expected plasma drug concentration levels, resulting in no statistically significant improvement on the primary endpoint [3][4] - The extension phase with a new batch of capsules (DP Batch B) showed statistically significant and clinically meaningful slowing of clinical progression compared to the initial batch [4] Treatment Response and Biomarkers - Treatment response increased progressively across DLB patient subgroups with lower plasma pTau181 levels, indicating a higher likelihood of patients without Alzheimer's disease (AD) co-pathology [2][5] - The analyses revealed a strong association between neflamapimod response and the absence of AD co-pathology, reinforcing confidence in the drug's potential to slow disease progression [2][5] Statistical Findings - Within-participant comparisons showed that at the lowest plasma pTau181 levels (<21 pg/mL), the average change in Clinical Dementia Rating Sum of Boxes (CDR-SB) was -1.11, indicating significant clinical improvement [6][7] - The mean change in the Alzheimer's Disease Cooperative Study — Clinical Global Impression of Change (ADCS-CGIC) score also demonstrated a greater effect at lower pTau181 levels [7][8] Future Plans - The company plans to initiate a global Phase 3 trial in the second half of 2026, focusing on patients with DLB enriched for those without AD co-pathology [16] - The planned trial will utilize a pTau181 cut-off level of <21 pg/mL, estimated to include 80% to 90% of patients without AD co-pathology [8][16]

Core Insights - CervoMed Inc. reported positive Phase 2b RewinD-LB clinical data and obtained alignment with FDA for Phase 3 trial design in dementia with Lewy bodies (DLB) [1][2] - The company anticipates multiple catalysts in the second half of 2026, including the initiation of the Phase 3 trial and topline data from other ongoing trials [1][2] Clinical Developments - CervoMed's lead program, neflamapimod, showed significant clinical benefits in DLB patients during the Phase 2b trial, with improvements in cognitive and functional outcomes [3][14] - The planned Phase 3 trial will involve approximately 300 patients and will focus on those without Alzheimer's disease co-pathology [3][11] Financial Performance - As of December 31, 2025, CervoMed had approximately $20.9 million in cash, down from $38.9 million in 2024, indicating a need for additional funding [7] - Grant revenue decreased to approximately $4.0 million in 2025 from $9.7 million in 2024 due to the completion of the RewinD-LB trial phases [8] - Research and Development (R&D) expenses increased to approximately $21.8 million in 2025 from $18.8 million in 2024, driven by personnel costs and clinical trial activities [9] Corporate Updates - CervoMed plans to present additional data at the AD/PD 2026 Scientific Conference, further supporting its Phase 3 trial design [11] - The company has strengthened its intellectual property portfolio with multiple patents issued in Europe, Japan, and China [11] Anticipated Milestones - The initiation of the Phase 3 trial for neflamapimod in DLB is expected in the second half of 2026, subject to funding [11][15] - Initial topline data from ongoing Phase 2a trials in ischemic stroke recovery and primary progressive aphasia are anticipated in the second half of 2026 [11][12]

1 Medicines for the Brain Corporate Presentation March 2026 NASDAQ: CRVO Forward-Looking Statements This presentation includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the CervoMed Inc. (Company), including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic eff ...

Core Insights - CervoMed is advancing its drug candidate neflamapimod for treating dementia with Lewy bodies (DLB), a condition with no approved treatments in the US or EU [1][6] - The company plans to initiate a Phase 3 trial in DLB patients, specifically targeting those without Alzheimer's disease co-pathology, in the second half of 2026 [6] Group 1: Clinical Trial Results - In the Phase 2b RewinD-LB trial, neflamapimod showed a statistically significant and clinically meaningful slowing of clinical progression in DLB patients without Alzheimer's disease co-pathology [2] - Secondary analyses will present new outcomes based on pre-specified plasma pTau181 levels, supporting the planned Phase 3 trial's patient selection criteria [2] Group 2: Upcoming Presentations - CervoMed will present findings at the AD/PD 2026 conference in Copenhagen, including an oral presentation on neflamapimod's treatment effects in DLB patients [5] - A scientific symposium sponsored by CervoMed will discuss advances in DLB research and new drug development strategies, featuring presentations from leading researchers [4] Group 3: Drug Development Strategy - Neflamapimod targets critical disease processes in neuroinflammation and neurodegeneration, aiming to inhibit a key enzyme involved in these processes [6] - The company is focusing on understanding the dose-response relationship of neflamapimod through new pharmacokinetic and pharmacodynamic analyses from the RewinD-LB trial [4]

Core Insights - CervoMed Inc. has completed a Phase 1 study of a new stable crystal form of neflamapimod, which shows a pharmacokinetic profile that overlaps with the active drug used in previous trials [1][2] - The company plans to initiate a Phase 3 trial for dementia with Lewy bodies (DLB) using a dosing regimen of 50mg three times daily (TID) to ensure therapeutic plasma drug concentrations are achieved [1][2][3] Group 1: Study Results and Dosing Regimen - The selected dose for the Phase 3 study is 50mg TID of the stable crystal form of neflamapimod, increased from 40mg to ensure adequate plasma concentrations [2][3] - The pharmacokinetic profiles of the new formulation and the previously used drug product batch (DP Batch B) are largely overlapping, indicating consistency in drug behavior [2][3] Group 2: Manufacturing and Formulation Improvements - CervoMed has developed a controlled manufacturing process that produces only the stable crystal form of neflamapimod, addressing previous issues with cross-batch variability and underperformance [3] - The new formulation aims to mitigate the challenges faced with earlier drug product batches that contained multiple solid-state forms, which affected bioavailability [3] Group 3: Clinical Development and Efficacy - Neflamapimod is an investigational drug targeting neuroinflammation and synaptic dysfunction, with potential applications in DLB and other degenerative brain disorders [4][7] - Clinical trials have shown that neflamapimod is generally well tolerated and has demonstrated efficacy in improving cognitive and functional outcomes in patients with DLB [5][6]

Core Viewpoint - CervoMed Inc. has announced that its investigational drug neflamapimod has been included in the EXPERTS-ALS platform for rapid testing in amyotrophic lateral sclerosis (ALS), with the first patient expected to be dosed by the end of 2026 [1][4] Group 1: Neflamapimod and Its Mechanism - Neflamapimod is an oral small molecule drug candidate that targets critical disease processes underlying neurodegenerative disorders by selectively inhibiting p38 MAP kinase, a key driver of neuroinflammation [6][11] - The drug has shown positive clinical activity in dementia with Lewy bodies, demonstrating a potent effect on blood biomarkers of neurodegeneration [3][8] - Neflamapimod is currently in clinical development for multiple indications, including dementia with Lewy bodies, recovery after ischemic stroke, and primary progressive aphasia [7][11] Group 2: EXPERTS-ALS Platform - EXPERTS-ALS is a UK-based platform designed to rapidly evaluate potential therapies for ALS through a randomized, multicenter trial that measures neurofilament light chain (NfL) levels, which correlate with disease progression [2][9] - The initial evaluation of neflamapimod will involve approximately 35 ALS participants over 18-24 weeks, with the potential to expand to a total of 80 patients [2] - The platform is funded by the UK National Institute for Health and Care Research and supported by various motor neuron disease charities [2][9] Group 3: Clinical Trial Insights - Previous clinical trials of neflamapimod have involved over 800 participants, showing it to be generally well tolerated and effective in improving dementia severity and functional mobility in patients with dementia with Lewy bodies [8] - The Phase 2a AscenD-LB trial and Phase 2b RewinD-LB trial provided evidence of neflamapimod's potential clinical benefits, particularly in patients without Alzheimer's disease co-pathology [8] Group 4: ALS Overview - Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting approximately 168,000 people worldwide, with no approved therapies to stop or reverse its progression [5]

Core Insights - The Phase 2b RewinD-LB trial of neflamapimod showed significant improvements in primary and key secondary outcomes, particularly in patients without Alzheimer's disease (AD) co-pathology [1][2] - Neflamapimod demonstrated a significant reduction in the neurodegeneration biomarker GFAP, indicating its potential to target the underlying mechanisms of dementia with Lewy bodies (DLB) [1][10] - CervoMed plans to initiate a Phase 3 registrational trial for neflamapimod in DLB patients in the second half of 2026 [1][9] Trial Results - The RewinD-LB trial included a randomized phase comparing neflamapimod to placebo, followed by an open-label extension phase [3][7] - In the extension phase, participants receiving a new batch of neflamapimod capsules achieved target plasma concentration levels, leading to significant improvements in clinical outcomes [4][5] - The primary endpoint, CDR-SB, showed a mean change that was 52% lower with the new batch compared to the initial batch, and 82% lower in patients without AD co-pathology [5][10] Safety and Tolerability - Neflamapimod was well-tolerated, with a low treatment discontinuation rate over 48 weeks [6][10] - Discontinuation due to liver enzyme elevation was 2.5% in the initial phase and 1.3% in the extension phase, with all events being reversible [6][10] Company Overview - CervoMed is a clinical-stage company focused on developing treatments for age-related brain disorders, with neflamapimod as its lead candidate [9][11] - The company aims to address critical disease processes underlying degenerative brain disorders through neflamapimod, which inhibits a key enzyme involved in neuroinflammation [9][11] Disease Context - Dementia with Lewy bodies (DLB) is the second most common progressive dementia after Alzheimer's, with no approved treatments available in the U.S. or EU [8][9] - DLB typically progresses more rapidly than Alzheimer's, often requiring nursing-home care within two years of diagnosis [8][9]